Pharmaceutical

Keytruda combination treatment for NSCLC falls short in Phase III

The Phase III KEYLYNK-006 study evaluating a Keytruda/Lynparza combination treatment failed to meet its primary endpoints.

Mar 22, 2024 - 00:00
Keytruda combination treatment for NSCLC falls short in Phase III
The Phase III KEYLYNK-006 study evaluating a Keytruda/Lynparza combination treatment failed to meet its primary endpoints.
Read the original article

Tags:

Previous Article

Nouscom extends Series C round to $82m for cancer vaccine trials

Next Article

Molecular glues are the latest craze in pharma research, but what are they?

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: House panel takes first steps toward reining in hospitals with ‘site-neutral’ changes

STAT+: House panel takes first steps toward reining in ...

May 17, 2023

FDA yet to find link between suicidal risk and GLP-1RA use

FDA yet to find link between suicidal risk and GLP-1RA use

Jan 13, 2024

STAT+: Pharmalittle: U.S. Chamber sues over Medicare price negotiations; FDA seeks new supplier for scarce cancer drug

STAT+: Pharmalittle: U.S. Chamber sues over Medicare pr...

Jun 12, 2023